BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 25941354)

  • 1. The regulatory role of invariant NKT cells in tumor immunity.
    McEwen-Smith RM; Salio M; Cerundolo V
    Cancer Immunol Res; 2015 May; 3(5):425-35. PubMed ID: 25941354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of NKT cells in cancer immunotherapy.
    Bae EA; Seo H; Kim IK; Jeon I; Kang CY
    Arch Pharm Res; 2019 Jul; 42(7):543-548. PubMed ID: 30859410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
    Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
    Front Immunol; 2019; 10():352. PubMed ID: 30881361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
    Hung JT; Huang JR; Yu AL
    J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.
    Wolf BJ; Choi JE; Exley MA
    Front Immunol; 2018; 9():384. PubMed ID: 29559971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
    Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
    Front Immunol; 2018; 9():1990. PubMed ID: 30298063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invariant NKT cells facilitate cytotoxic T-cell activation via direct recognition of CD1d on T cells.
    Qin Y; Oh S; Lim S; Shin JH; Yoon MS; Park SH
    Exp Mol Med; 2019 Oct; 51(10):1-9. PubMed ID: 31653827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.
    Takami M; Ihara F; Motohashi S
    Front Immunol; 2018; 9():2021. PubMed ID: 30245690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials.
    Zhang Y; Springfield R; Chen S; Li X; Feng X; Moshirian R; Yang R; Yuan W
    Front Immunol; 2019; 10():1126. PubMed ID: 31244823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycolipid Stimulation of Invariant NKT Cells Expands a Unique Tissue-Resident Population of Precursors to Mature NK Cells Endowed with Oncolytic and Antimetastatic Properties.
    Choi J; Rudak PT; Lesage S; Haeryfar SMM
    J Immunol; 2019 Oct; 203(7):1808-1819. PubMed ID: 31462506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity.
    Chennamadhavuni D; Saavedra-Avila NA; Carreño LJ; Guberman-Pfeffer MJ; Arora P; Yongqing T; Pryce R; Koay HF; Godfrey DI; Keshipeddy S; Richardson SK; Sundararaj S; Lo JH; Wen X; Gascón JA; Yuan W; Rossjohn J; Le Nours J; Porcelli SA; Howell AR
    Cell Chem Biol; 2018 May; 25(5):571-584.e8. PubMed ID: 29576533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-Specific Roles of NKT Cells in Tumor Immunity.
    Terabe M; Berzofsky JA
    Front Immunol; 2018; 9():1838. PubMed ID: 30158927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
    Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
    Front Immunol; 2018; 9():1266. PubMed ID: 29928278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
    Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
    Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CD1c enhances human invariant NKT cell activation by α-GalCer.
    Fox LM; Miksanek J; May NA; Scharf L; Lockridge JL; Veerapen N; Besra GS; Adams EJ; Hudson AW; Gumperz JE
    Cancer Immun; 2013; 13():9. PubMed ID: 23885215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Invariant NKT in Autoimmune Liver Disease: Can Vitamin D Act as an Immunomodulator?
    Smyk DS; Mavropoulos A; Mieli-Vergani G; Vergani D; Lenzi M; Bogdanos DP
    Can J Gastroenterol Hepatol; 2018; 2018():8197937. PubMed ID: 30046564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-glycosidic compounds can stimulate both human and mouse iNKT cells.
    Jukes JP; Gileadi U; Ghadbane H; Yu TF; Shepherd D; Cox LR; Besra GS; Cerundolo V
    Eur J Immunol; 2016 May; 46(5):1224-34. PubMed ID: 26873393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
    Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
    Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redirecting iNKT Cell Antitumor Immunity with α-GalCer/CD1d-scFv Fusion Proteins.
    Zhang L; Donda A
    Methods Mol Biol; 2021; 2388():175-180. PubMed ID: 34524672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.